The Technical Analyst
Catalyst Biosciences Inc [CBIO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Catalyst Biosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.65% $0.511
America/New_York / 30 okt 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 19.42 mill |
| EPS: | -20.70 |
| P/E: | -0.0247 |
| Earnings Date: | Oct 25, 2023 |
| SharesOutstanding: | 37.98 mill |
| Avg Daily Volume: | 0.437 mill |
| RATING 2023-10-30 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | ||||
| Ebit | n/a | |||||
| Asset | ||||||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0247 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0247 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.474 - 0.548 ( +/- 7.24%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-11-20 | Luo Ying | Buy | 3 350 897 | Stock Option (Right to Buy) |
| 2023-10-30 | Luo Ying | Buy | 2 840 376 | Common Stock |
| 2023-11-20 | Luo Ying | Buy | 2 262 755 | Stock Option (Right to Buy) |
| 2023-11-20 | Ye Weiguo | Buy | 1 665 115 | Stock Option (Right to Buy) |
| 2023-11-20 | Ma Songjiang | Buy | 4 510 047 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 23.38 |
| Last 85 transactions |
| Buy: 88 748 347 | Sell: 111 334 812 |
Forecast:
01:40 - $0.536
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.511 (-2.65% ) |
| Volume | 0.461 mill |
| Avg. Vol. | 0.437 mill |
| % of Avg. Vol | 105.36 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CBIO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CBIO
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
Latest Press Releases
2023-10-30 12:00:00 - Press Release
Catalyst Biosciences Announces Completion Of Business Combination With Beijing Continent Pharmaceuticals And Implementation Of Name Change And Reverse Stock Split
The combined company will operate as “gyre therapeutics, inc.” with its common stock traded on nasdaq under trading symbol “gyre” effective tuesday, october 31, 2023
2023-07-21 18:18:00 - Press Release
Catalyst Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Merger Of Catalyst Biosciences, Inc. - Cbio
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the merger of catalyst biosciences, inc. (nasdaqcm: cbio) and gni group ltd. ksf is seeking to determine whether the transaction and the process that led to it are adequate and fair to the company's shareholders. if you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost.
2023-03-07 02:41:00 - Press Release
Shareholder Alert: Weiss Law Reminds Dcp, Mlvf, Shbi, And Cbio Shareholders About Its Ongoing Investigations
New york , march 7, 2023 /prnewswire/ -- if you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: joshua rubin, esq. weiss law305 broadway, 7th floor new york, ny 10007mlvf (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com dcp midstream, lp (nyse: dcp) weiss law is investigating possible violations of law connected with the proposed acquisition of dcp midstream, lp (nyse: dcp) by phillips 66.
2022-12-30 20:43:00 - Press Release
Catalyst Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Catalyst Biosciences, Inc. - Cbio
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating catalyst biosciences, inc. (nasdaqcm: cbio) in connection with its acquisition of the f351 program, a next-generation fibrosis drug, from gni group ltd. and, in a separate transaction, its acquisition of a controlling interest in beijing continent for 6,266,521 shares of common stock and 12,340 shares of a new series of preferred stock (series x) with economic rights equivalent to catalyst’s common stock. each share of series x preferred stock is convertible into 10,000 shares of common stock, subject to stockholder approval under nasdaq rules and subject to a beneficial ownership conversion blocker...
2022-12-28 07:23:00 - Press Release
Cbio Stock Alert: Halper Sadeh Llc Is Investigating Whether The Merger Of Catalyst Biosciences, Inc. Is Fair To Shareholders
New york--(business wire)--halper sadeh llc, an investor rights law firm, is investigating whether the merger of catalyst biosciences, inc. (nasdaq: cbio) and gni group ltd. is fair to catalyst shareholders. halper sadeh encourages catalyst shareholders to click here to learn more about their legal rights and options or contact daniel sadeh or zachary halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. the investigation concerns whether catalyst and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for catalyst shareholders; and (2) disclose all material information necessary for catalyst shareholders to adequately assess and value the merger consideration...
Latest News
2023-02-28 08:00:03 - InvestorPlace
Why Is Catalyst Biosciences (CBIO) Stock Up 55% Today?
Catalyst Biosciences (NASDAQ: CBIO ) stock is rocketing higher on Tuesday after the company announced an asset purchase agreement with GC Biopharma. That agreement has Catalyst Biosciences selling three of its programs related to orphan hematology disorders to the company.
2022-08-15 12:23:49 - Seeking Alpha
Catalyst Biosciences: Shareholders Should Reap Benefits From Owning The Stock
Catalyst Biosciences is highly committed to its cash distribution plan to shareholders of up to $65 million in the near future, with only a $58 million market capitalization. If the proxy contest is cleared up between Catalyst and JDS1 and goes in favor of the executives of Catalyst, shareholders should expect an initial cash distribution of $45 million.
2022-06-28 10:50:24 - Zacks Investment Research
Has Catalyst Biosciences (CBIO) Outpaced Other Medical Stocks This Year?
Here is how Catalyst Biosciences, Inc. (CBIO) and Humana (HUM) have performed compared to their sector so far this year.
2022-06-17 11:03:35 - PennyStocks
5 Penny Stocks To Watch With High Short Interest, Are They A Buy Now?
Penny stocks are red hot right now if you know where to… The post 5 Penny Stocks To Watch With High Short Interest, Are They A Buy Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-05-25 20:21:36 - PennyStocks
Hot Penny Stocks to Buy This Week? 3 to Watch
Which penny stocks are you watching right now? The post Hot Penny Stocks to Buy This Week?
2022-05-24 12:30:01 - PennyStocks
Penny Stocks To Buy Now? 3 With Unusual Options Activity To Watch
2022-05-23 10:36:13 - InvestorPlace
Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?
Catalyst Biosciences (CBIO) stock is rocketing higher on Monday after announcing the sale of its protease medicines portfolio. The post Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?
2022-05-23 10:01:05 - Benzinga
Why Catalyst Biosciences Shares Are Skyrocketing Today
Catalyst Biosciences Inc (NASDAQ: CBIO) shares are trading higher by 180.26% at $1.06 after the company announced it sold its complement portfolio for $60 million. A definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has allowed Vertex to acquire.
2022-05-23 10:01:04 - Benzinga
Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex
Catalyst Biosciences Inc (NASDAQ: CBIO) has agreed to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) for $60 million. "This sale is part of the ongoing strategic process that we announced in.
2022-05-23 09:34:22 - PennyStocks
Penny Stocks To Buy Now? 4 To Watch Under $1
